Dianthus TherapeuticsSTU:87E 22 Quick Ratio is 29.25 as of Mar. 2026, which is 83% above its 10-year median of 15.99. GuruFocus rates STU:87E with a GF Score™ of 22/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Dianthus Therapeutics ranks better than 96.24% on this metric.
Dianthus Therapeutics has a quick ratio of 29.25. It generally indicates good short-term financial strength.
The historical rank and industry rank for Dianthus Therapeutics's Quick Ratio or its related term are showing as below:
STU:87E'
s Quick Ratio Range Over the Past 10 Years
Min: 1.75 Med: 15.99 Max: 42.52
Current: 29.25
During the past 5 years, Dianthus Therapeutics's highest Quick Ratio was 42.52. The lowest was 1.75. And the median was 15.99.
STU:87E's Quick Ratio is ranked better than 96.24% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs STU:87E: 29.25
Dianthus Therapeutics (STU:87E) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Dianthus Therapeutics Quick Ratio Related Terms
Dianthus Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Dianthus Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:87E vs CAI, TNGX, MANE: Quick Ratio Comparison
For the Biotechnology subindustry, Dianthus Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dianthus Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Dianthus Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Dianthus Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dianthus Therapeutics (STU:87E) has a Quick Ratio of 29.25 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Dianthus Therapeutics and its competitors. This is 83% above median its historical median of 15.99. Over the past decade, Dianthus Therapeutics' Quick Ratio has ranged from 1.75 to 42.52. According to the industry distribution chart, Dianthus Therapeutics ranks #53 out of 1410 companies in the Biotechnology industry, placing it in the top 3.8%.
Is Dianthus Therapeutics' Quick Ratio too high?
Dianthus Therapeutics' current Quick Ratio of 29.25 is 83% above median its 10-year median of 15.99. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 42.52. The Biotechnology industry median Quick Ratio is 3.60. Dianthus Therapeutics' value of 29.25 is 712.5% above this industry median. Based on the distribution chart, Dianthus Therapeutics ranks #53 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Quick Ratio compare to CAI and TNGX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #53 out of 1410 companies for Quick Ratio. This places Dianthus Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Dianthus Therapeutics' value of 29.25 is 712.5% above this benchmark. Historically, Dianthus Therapeutics' own Quick Ratio has ranged from 1.75 to 42.52 over the past decade. While the company's 10-year median is 15.99 vs. the industry median of 3.60, Dianthus Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dianthus Therapeutics's current Quick Ratio of 29.25 is 712.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Dianthus Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dianthus Therapeutics's current Quick Ratio is 29.25, which is 83% above median its own 10-year median of 15.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (STU:87E) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €82.00 — trading 3141.1% above its estimated fair value. The current Quick Ratio is 29.25, which is 83% above median its 10-year median of 15.99 and 712.5% above the Biotechnology industry median of 3.60. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Dianthus Therapeutics (STU:87E), the current Quick Ratio is 29.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?
Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued.
The current stock price of €82.00 is trading 3141.1% above its estimated GF Value™ of €2.53.
GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:87E:
Quick Ratio: 29.25 (83% above median its 10-year median of 15.99)
GF Value™: €2.53 vs. price of €82.00 (3141.1% above fair value)
Industry Position: 712.5% above the Biotechnology median (#53 of 1410)
No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score
Get the complete analysis for STU:87E
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:87E has been successfully added to your 
